Health Care · Surgical & Medical Instruments & Apparatus

NPCE NeuroPace Inc SEC Filings & Insider Trading Activity 2026

company
CIK 152828780 filings
Russell 2000

NPCE at a glance

NeuroPace Inc (NPCE, SEC CIK 1528287) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), NeuroPace Inc (NPCE) reported revenue of $100.0 million (up 25.1% from FY2024) and a net loss of $21.5 million. Diluted EPS was -$0.66.
  • As of September 30, 2026, 22 institutional investment managers tracked by SignalX reported holding NeuroPace Inc (NPCE) shares worth $117.7 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Huennekens R Scott on November 18, 2026 of 12,500 shares at $8.29 per share.
  • In the last 90 days, NPCE insiders reported 3 open-market purchases ($302K) and 0 open-market sales ($0) on Form 4, a net purchase of $302K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$100.0M
+25.1% vs prior year
Insiders · 90 days
3 buys · 0 sells
Net +$302K
13F holders
22 funds
$117.7M · +0 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $23.1M, down 1% YoY from $23.4M, driven by $0.6M lower service revenue
  • Gross margin 84.3% vs 82.1% YoY, reflecting improved labor absorption and standard-cost benefits
  • RNS System revenue up $0.3M, offsetting service-revenue decline; DIXI sales discontinued
  • Cash, equivalents and short-term investments $49.2M, with $59.2M outstanding debt at September 30
  • Operating cash flow use $12.6M vs $11.5M YoY; continued losses and negative cash flows expected near term

Risk Factors

  • Newly added QMSR risk: QSR superseded on February 2, 2026, raising compliance requirements for the Mountain View manufacturing facility
  • Most materially updated regulatory risk: FDA staffing cuts and leadership changes could delay expanded-label reviews for IGE and ages 12 to 17
  • Healthcare reform risk: OBBBA expected to reduce Medicaid spending and enrollment, potentially shrinking coverage for RNS procedures
  • Operational risk: single-source suppliers include Micro Systems Technologies and Integer for printed circuit assemblies and batteries
  • Margin risk: changing tariff framework could weaken RNS gross margins and revenue projections despite limited non-U.S. supply-chain activity

AI summary of the NPCE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release covers NeuroPace’s financial results for the quarter ended September 30, 2026
  • Investors should review Exhibit 99.1 for revenue, profitability, cash flow and management commentary

Item EX-99.1: Item EX-99.1

  • Q3 revenue $23.1M, down 1.1% YoY, with RNS revenue $22.9M, up 1.4%, signaling stalled commercial momentum
  • GAAP net loss narrowed to $3.3M from $4.9M, while Adjusted EBITDA improved to $0.4M from negative $1.3M
Filed Aug 11, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release announces NeuroPace’s financial results for the quarter ended June 30, 2026
  • Exhibit 99.1 contains the detailed quarterly financial results and management commentary

Item EX-99.1: Item EX-99.1

  • Q2 revenue $22.8M, up 17%; RNS revenue $22.5M, up 21.3%, signaling continued adoption in focal epilepsy
  • Net loss narrowed to $6.2M from $10.0M; Adjusted EBITDA loss improved to $2.8M from $4.9M
Filed Jul 28, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • FDA found the IGE PMA supplement not approvable in its current form, delaying potential RNS indication expansion
  • NeuroPace plans a Submission Issue Request and additional NAUTILUS clinical evidence to address FDA questions

Item 7.01: Regulation FD Disclosure

  • FDA found RNS System indication expansion not approvable in current form
  • Requested additional clinical evidence for antiseizure medication-resistant IGE with GTC seizures

AI summaries of NPCE 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for NPCE

Don't miss the next NPCE filing

  • Alerts as it files. A push when NPCE files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut NPCE, by share count.
  • Ask anything. An AI agent that reads every NPCE filing and answers with sources.

NPCE alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Huennekens R ScottBuyNov 18, 2026$8.29
Becker JoelBuyNov 17, 2026$8.35
Williams Patrick F.BuyNov 17, 2026$8.34
Morrell MarthaFSep 24, 2026$13.97
Williams Patrick F.FSep 20, 2026$14.28
Becker JoelFSep 3, 2026$14.75
Morrell MarthaFAug 27, 2026$14.13
Becker JoelFAug 27, 2026$14.13

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$79.9M$100.0M
Gross Profit-$59.1M$77.2M
Operating Income--$21.7M-$16.3M
Net Income--$27.1M-$21.5M
Gross Margin-73.9%77.2%
Op. Margin--27.1%-16.3%
Net Margin--34.0%-21.5%
Balance Sheet
Total Assets$107.7M$94.6M$105.6M
Equity$20.7M$8.0M$19.0M
ROE--338.7%-112.8%
Per Share
EPS-$-0.93$-0.66
Cash Flow
Operating CF--$17.9M-$11.0M
CapEx-$306K$332K

Source: XBRL data in NeuroPace Inc (NPCE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate NPCE share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
NPCE shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202622$117.7M
Q2 202622$141.8M
Q1 202622$110.4M
Q4 202519$137.0M
Q3 202517$84.8M
Q2 202520$89.0M
Q1 202516$63.7M
Q4 202411$27.7M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 149 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

NPCE filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
10-QNov 12, 2026Analysis
8-KNov 12, 2026Analysis-
4Sep 25, 2026--
4Sep 21, 2026--
4Sep 4, 2026--
4Aug 28, 2026--
4Aug 28, 2026--
8-KAug 11, 2026Analysis-
10-QAug 11, 2026Analysis
8-KJul 28, 2026Analysis-
4Jun 25, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
8-KJun 8, 2026Analysis
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 4, 2026-

Related Health Care companies

All Health Care →

NPCE SEC filings: frequently asked questions

Are NPCE insiders buying or selling?

In the last 90 days, NeuroPace Inc (NPCE) officers, directors and 10% owners reported 3 open-market purchases worth $302,103 by 3 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold NPCE stock?

As of September 30, 2026, the largest NeuroPace Inc (NPCE) holders among the 13F filers tracked by SignalX were Morgan Stanley ($35.3 million), BlackRock ($34.0 million), Vanguard Capital Management LLC ($17.0 million), State Street Corp ($7.8 million), D.E. Shaw & Co ($3.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was NPCE's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), NeuroPace Inc (NPCE) reported revenue of $100.0 million (up 25.1% from FY2024) and a net loss of $21.5 million. Diluted EPS was -$0.66. The figures come from the XBRL data in the 10-K.

What did NPCE report in its latest 8-K?

NeuroPace Inc (NPCE) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers NeuroPace’s financial results for the quarter ended September 30, 2026.

What are the latest NPCE SEC filings?

NeuroPace Inc (NPCE) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 18, 2026.

What is NPCE's SEC CIK number?

NeuroPace Inc (NPCE)'s SEC Central Index Key (CIK) is 1528287. EDGAR lists every NPCE filing under that number.

Ask anything about NPCE

The research agent reads NPCE's filings, financials, insider trades and 13F holders, then answers with sources.